Posted by Michael Wonder on 10 Sep 2025
Teva’s emrusolmin granted US FDA fast track designation for treatment of multiple system atrophy
9 September 2025 - Teva Pharmaceuticals today announced that the US FDA granted fast track designation for Teva’s investigational therapy emrusolmin (TEV-56286) for the treatment of multiple system atrophy.
Emrusolmin is part of a strategic collaboration with MODAG GmbH and is currently being evaluated in a Phase 2 trial to assess its efficacy and safety. The US FDA granted orphan drug designation to emrusolmin for MSA in 2022.
